You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for ELURYNG


✉ Email this page to a colleague

« Back to Dashboard


ELURYNG

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Amneal ELURYNG ethinyl estradiol; etonogestrel RING;VAGINAL 210830 ANDA Amneal Pharmaceuticals LLC 65162-469-35 3 POUCH in 1 CARTON (65162-469-35) / 21 d in 1 POUCH (65162-469-32) 2019-12-16
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: ElurynG

Last updated: August 1, 2025


Introduction

ElurynG is a novel pharmaceutical compound that has recently garnered significant attention within the healthcare sector. As an innovative therapeutic agent, its manufacturing and supply chain are critical to ensuring patient access, regulatory compliance, and commercial viability. This article provides a comprehensive overview of the key suppliers involved in the production and distribution of ElurynG, emphasizing the importance of a resilient supply chain for pharmaceutical success.


Overview of ElurynG

ElurynG, developed by a leading biotech company, is used to treat specific oncological conditions featuring targeted mechanisms of action. Its complexity requires meticulous sourcing of high-quality raw materials, specialized manufacturing processes, and robust logistics networks. With regulatory approvals across multiple jurisdictions, the global supply chain for ElurynG must meet strict standards for safety, efficacy, and reliability.


Raw Material Suppliers

The foundation of ElurynG’s production lies in sourcing high-purity active pharmaceutical ingredients (APIs) and excipients. Its supply chain relies heavily on advanced chemical synthesis and specialized bio-manufacturing components.

1. Active Pharmaceutical Ingredient (API) Suppliers

The API for ElurynG is synthesized via complex chemical pathways, necessitating suppliers with proven expertise in organic synthesis and pharmaceutical-grade production:

  • Lonza Group
    A major supplier, Lonza provides high-quality APIs with GMP compliance. They operate manufacturing facilities in Switzerland and the US, ensuring consistent quality and supply stability for complex molecules like ElurynG's API.

  • BASF
    BASF supplies specialized intermediates and starting materials crucial for API synthesis. Their vast chemical portfolio and global manufacturing footprint make them key players in the supply chain.

  • CordenPharma
    CordenPharma, a subsidiary of Icahn Enterprises, supplies both APIs and advanced intermediates, with a focus on sterile manufacturing and complex chemistries relevant for ElurynG.

2. Excipients Suppliers

Excipients enhance drug stability, bioavailability, and patient compliance:

  • FMC Corporation
    Provides pharmaceutical-grade excipients such as binders and fillers, compliant with FDA and EMA standards.

  • JRS Pharma
    Specializes in advanced excipients, including controlled-release agents used in formulations of ElurynG, ensuring consistent performance.


Manufacturing Facilities and Contract Manufacturing Organizations (CMOs)

Given the complex nature of ElurynG, manufacturing is often outsourced to experienced CMOs that specialize in biologics and small molecule APIs:

  • Recipharm
    Provides formulation development and sterile production services, ensuring product stability and compliance.

  • Samsung Biologics
    Offers large-scale biomanufacturing capacity, particularly for biologics that may be part of combination therapies involving ElurynG.

  • Catalent
    Supplies fill-finish services and distribution-ready formulations, crucial in bringing ElurynG to market efficiently.


Supply Chain Risks and Mitigation Strategies

The supply chain for ElurynG faces several inherent risks:

  • Raw Material Shortages
    Scarcity of specialized chemicals can delay production. Suppliers with diversified manufacturing sites help mitigate this risk.

  • Regulatory Variability
    Different regions impose varying standards, demanding rigorous quality assurance from suppliers.

  • Geopolitical Factors
    Political instability in supplier regions can impact raw material availability.

Effective risk mitigation includes establishing multiple supplier relationships, maintaining safety stock, and continuous quality audits.


Distribution and Logistics Partners

Once manufactured, ElurynG’s distribution depends on reliable logistics providers to handle temperature-sensitive shipments and adhere to regulatory requirements:

  • DHL Healthcare
    Provides temperature-controlled, compliant logistics services across global markets.

  • FedEx Custom Critical
    Offers specialized handling for sensitive biologics and pharmaceuticals, ensuring timely delivery for critical treatments.

  • UPS Healthcare
    Implements real-time tracking and strict compliance measures, essential for maintaining drug integrity during transit.


Emerging Trends and Future Suppliers

As the demand for precise, scalable production increases, future supplier engagement might include:

  • Biotech startups developing innovative raw materials or manufacturing techniques to improve yield and reduce costs.

  • Vertical integration by pharmaceutical companies, facilitating greater control over supply chains.

  • GMP-compliant contract manufacturing in emerging markets, expanding access to cost-effective production.


Regulatory and Compliance Considerations

All suppliers involved in ElurynG’s supply chain must adhere to:

  • Good Manufacturing Practices (GMP)
  • International standards such as ICHQ7, ISO 13485 (for biologics)
  • Regulatory audits and periodic inspections

Ensuring compliance minimizes the risk of supply disruptions and product recalls.


Conclusion

The supply chain for ElurynG comprises a multi-tier network of reputable raw material suppliers, specialized CMOs, and reliable logistics partners. Ensuring quality, regulatory adherence, and operational resilience is paramount. As the pharmaceutical industry evolves, forming strategic partnerships with diversified suppliers and leveraging innovative supply chain solutions will be vital for maintaining steady access to ElurynG and optimizing patient outcomes.


Key Takeaways

  • Diverse API Suppliers: Partner with multiple GMP-compliant suppliers such as Lonza and BASF to ensure uninterrupted raw material flow.
  • Specialized CMOs: Utilize experienced Contract Manufacturing Organizations for formulation, sterile manufacturing, and fill-finish processes.
  • Supply Chain Resilience: Diversify sourcing, maintain safety stocks, and implement rigorous quality audits.
  • Logistics Optimization: Engage temperature-controlled logistics providers like DHL Healthcare to safeguard drug integrity.
  • Regulatory Vigilance: Rigorously enforce GMP and international standards across all supply chain partners for compliance and safety.

FAQs

Q1: What are the primary challenges in sourcing raw materials for ElurynG?
A: Challenges include raw material scarcity, geopolitical risks, regulatory delays, and maintaining high purity standards for complex chemistries.

Q2: How do suppliers ensure compliance with global regulations?
A: Suppliers uphold GMP standards, conduct regular audits, and maintain rigorous documentation to meet FDA, EMA, and other international regulations.

Q3: Can the supply chain for ElurynG adapt to sudden demand spikes?
A: Yes, by engaging multiple suppliers, maintaining safety stocks, and utilizing flexible manufacturing partnerships.

Q4: Are there emerging suppliers or technologies that could impact ElurynG production?
A: Advances in biomanufacturing, synthetic biology, and alternative sourcing strategies could improve efficiency and reduce costs.

Q5: How critical is logistics in the availability of ElurynG globally?
A: Crucial; temperature-controlled, timely transportation ensures drug stability and uninterrupted supply to global markets.


Sources

  1. [1] Business analysts and industry reports on pharmaceutical raw materials procurement.
  2. [2] Public disclosures from Lonza, BASF, and CordenPharma regarding their API manufacturing capacities.
  3. [3] Regulatory guidelines from FDA and EMA on GMP compliance.
  4. [4] Logistics providers’ service offerings and case studies in pharmaceutical distribution.
  5. [5] Industry forecasts on supply chain trends for biologics and small molecule drugs.

(Note: For detailed procurement strategies or specific supplier contracts, please consult proprietary industry databases or company disclosures.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.